Immunotherapy News and Research

Latest Immunotherapy News and Research

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Janssen Research & Development, LLC today announced positive results from a pivotal Phase 2 global registration study (MCD2001) suggesting siltuximab, an investigational compound, along with best supportive care, exhibited statistically significant efficacy and a tolerable safety profile compared with placebo and BSC in treating patients with the rare disorder Multicentric Castleman's Disease who are HIV-negative and human herpes virus 8-negative.

8 Dec 2013

CEL-SCI gets approval to start enrollment for Multikine Phase III study for head and neck cancer

Further advancing one of the largest Phase III trials for head and neck cancer in the world, CEL-SCI Corporation announced today that it has received approval from the Agency for Medicaments and Medical Devices of the government of Bosnia and Herzegovina to begin enrollment of subjects into the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection).

5 Dec 2013

Researchers find correlation between biomarker and patient’s ability to respond to Imprime PGG

Biothera researchers have broadened their understanding of a biomarker that may enable doctors to predict which cancer patients will best respond to Imprime PGG®, the company's immunotherapy in Phase 3 drug development for colorectal cancer.

5 Dec 2013

New method for counting tumor-fighting cells to predict ovarian cancer

One way to predict survival of many types of cancer is by counting the number of tumor-attacking immune cells that have migrated into the tumor in an effort to eradicate it - a sign of the body's immune response to the cancer. However, quantifying these armies of immune cells has been difficult - until now.

5 Dec 2013

Tackling orphan diseases: an interview with Damian Marron, CEO, TxCell

The exact definition of orphan diseases varies depending on where you are in the world. In the EU it's defined as a prevalence of less than 1 in 2,000, which equates to about 250,000 patients across the EU.

4 Dec 2013

Better understanding of cancer evolution could help in early detection of cancers

A new appreciation of how cancer cells evolve could help scientists design better screening methods to catch cancer before it advances.

4 Dec 2013

Top cancer research centers to establish new biotechnology company focused on cancer immunotherapy

The Fred Hutchinson Cancer Research Center (Fred Hutch) and Memorial Sloan-Kettering Cancer Center (MSKCC), along with pediatric partner Seattle Children's Research Institute, have joined forces to launch Juno Therapeutics Inc., a new biotechnology company focused on bringing forward novel immunotherapies for cancer.

4 Dec 2013

TxCell receives Manufacturing Accreditation from ANSM for cell therapy production site in France

TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen-specific regulatory T-cells (Ag-Tregs) for chronic inflammatory and autoimmune diseases, announces today that it received a Manufacturing Accreditation delivered by the French National Agency for Drug Safety. The status has been received for its cell therapy production site in Besançon, France.

3 Dec 2013

Newly identified protein could prove promising new drug target for AIDS

Researchers have identified a protein that causes loss of function in immune cells combatting HIV. The scientists report in a paper appearing online Dec. 2 in the Journal of Clinical Investigation that the protein, Sprouty-2, is a promising target for future HIV drug development, since disabling it could help restore the cells' ability to combat the virus that causes AIDS.

2 Dec 2013

Ascend, 3M partner to develop and evaluate novel immunotherapy treatments for cancer

Ascend Biopharmaceuticals today announces that is has entered into an agreement with 3M Drug Delivery Systems to evaluate 3M’s Toll-Like Receptor 7/8 (TLR7/8) agonist 3M-051 in combination with Ascend’s proprietary cancer vaccine technology. The collaboration will support the creation and preclinical assessment of novel immunotherapy treatments to be potentially used for a number of different solid tumor types.

29 Nov 2013

UMass Medical School licenses "anti-gal" technology to Agalimmune

The University of Massachusetts Medical School has licensed "anti-gal" technology developed by Professor of Surgery and Medicine Uri Galili, PhD, to newly formed biopharmaceutical company Agalimmune Ltd. for the purpose of developing innovative immunotherapies for the treatment of solid tumor cancers. Agalimmune is supported by an investment group comprising Loxbridge Research LLP and Animatrix Capital LLP and is based in London and California.

27 Nov 2013

Agalimmune established to develop innovative immunotherapeutics for treatment of cancer

Agalimmune Ltd, a biopharmaceutical company, has been created to develop innovative immunotherapeutics for the treatment of cancer, with a focus on solid tumours.

26 Nov 2013

Transgene welcomes SillaJen’s intention to acquire Jennerex

Transgene SA (Paris:TNG) said today that it welcomed the announcement by SillaJen, Inc. of its intention to acquire Jennerex, Inc. and has consequently given its consent to the definitive merger agreement.

26 Nov 2013

SillaJen executes definitive merger agreement to acquire Jennerex

SillaJen, Inc., a privately-held biotherapeutics and contract research company focused on the development of targeted biological products for cancer, announced today that it had executed a definitive merger agreement to acquire San Francisco-based Jennerex, Inc.

26 Nov 2013

Scientists find link between airborne allergies and risk of blood cancers in women

A team of scientists looking into the interplay of the immune system and cancer have found a link between a history of airborne allergies - in particular to plants, grass and trees - with risk of blood cancers in women.

25 Nov 2013

Mouse study highlights importance of microorganisms in optimal cancer treatment outcomes

...

22 Nov 2013

Tasquinimod drug effective for men with metastatic castration-resistant prostate cancer

An investigational prostate cancer treatment slows the disease's progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute.

20 Nov 2013

Serametrix launches new MDSC-based blood test for cancer patients

Serametrix Corporation has announced the launch of an important new blood test for cancer patients. The test measures a patient's level of circulating Myeloid Derived Suppressor Cells (MDSCs) that are known to decrease anti-tumor immunity and are associated with poor survival rates in cancer patients.

20 Nov 2013

Generex Biotechnology provides update on Phase II trial of AE37 breast cancer vaccine

Generex Biotechnology Corporation today announced that it has reached a pre-specified point in the ongoing Phase II trial of its AE37 breast cancer vaccine to initiate its primary efficacy analysis. The drug is a novel immunotherapeutic cancer vaccine being developed by the Company's wholly-owned subsidiary, Antigen Express, Inc. A previously released positive interim analysis showed a strong trend toward reduced relapse in breast cancer patients receiving the AE37 vaccine.

18 Nov 2013

£20M research centre opened to investigate exciting new therapies for neurodegenerative diseases

A specialist £20 million research centre, funded by the Wolfson Foundation and dedicated to carrying out first-in-human studies, opens in London today (15th November). Researchers at the Leonard Wolfson Experimental Neurology Centre (LWENC) will investigate exciting new therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's.

16 Nov 2013

Immunotherapy News and Research

Latest Immunotherapy News and Research

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

CEL-SCI gets approval to start enrollment for Multikine Phase III study for head and neck cancer

Researchers find correlation between biomarker and patient’s ability to respond to Imprime PGG

New method for counting tumor-fighting cells to predict ovarian cancer

Tackling orphan diseases: an interview with Damian Marron, CEO, TxCell

Better understanding of cancer evolution could help in early detection of cancers

Top cancer research centers to establish new biotechnology company focused on cancer immunotherapy

TxCell receives Manufacturing Accreditation from ANSM for cell therapy production site in France

Newly identified protein could prove promising new drug target for AIDS

Ascend, 3M partner to develop and evaluate novel immunotherapy treatments for cancer

UMass Medical School licenses "anti-gal" technology to Agalimmune

Agalimmune established to develop innovative immunotherapeutics for treatment of cancer

Transgene welcomes SillaJen’s intention to acquire Jennerex

SillaJen executes definitive merger agreement to acquire Jennerex

Scientists find link between airborne allergies and risk of blood cancers in women

Mouse study highlights importance of microorganisms in optimal cancer treatment outcomes

Tasquinimod drug effective for men with metastatic castration-resistant prostate cancer

Serametrix launches new MDSC-based blood test for cancer patients

Generex Biotechnology provides update on Phase II trial of AE37 breast cancer vaccine

£20M research centre opened to investigate exciting new therapies for neurodegenerative diseases

Event guide: 7th Allogeneic Cell Therapies Summit eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Immunotherapy News and Research

Latest Immunotherapy News and Research

Event guide: 7th Allogeneic Cell Therapies Summit eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in